Curcumin, at the molecular level, has been shown to exhibit anti-inflammatory activity by suppressing numerous cellular signaling pathways including NF-κB, STAT3, Nrf2, ROS and COX-2.
Numerous studies have shown that it is a very powerful antimicrobial agent and has been shown to be active against a variety of chronic conditions, including various types of cancer, diabetes, obesity, cardiovascular, pulmonary, neurological and autoimmune diseases.
In addition, this compound has also been shown to be synergistic with resveratrol, catechins, quercetin and genistein.
To date, more than 100 different clinical trials have been completed with curcumin, which clearly demonstrates its safety, tolerability and efficacy against various chronic diseases in humans.
However, more clinical trials are needed.
SOURCE: Br J Pharmacol 2017
